MX2012001461A - Preparacion farmaceutica, de administracion oral, que contiene insulina. - Google Patents

Preparacion farmaceutica, de administracion oral, que contiene insulina.

Info

Publication number
MX2012001461A
MX2012001461A MX2012001461A MX2012001461A MX2012001461A MX 2012001461 A MX2012001461 A MX 2012001461A MX 2012001461 A MX2012001461 A MX 2012001461A MX 2012001461 A MX2012001461 A MX 2012001461A MX 2012001461 A MX2012001461 A MX 2012001461A
Authority
MX
Mexico
Prior art keywords
pharmaceutical preparation
preparation containing
orally administerable
containing insulin
administerable pharmaceutical
Prior art date
Application number
MX2012001461A
Other languages
English (en)
Spanish (es)
Inventor
Szilvassy Dr Zoltan
Peitl Dr Barna
Nemeth Dr Jozsef
Original Assignee
Cera Med Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cera Med Kft filed Critical Cera Med Kft
Publication of MX2012001461A publication Critical patent/MX2012001461A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2012001461A 2009-08-03 2010-08-02 Preparacion farmaceutica, de administracion oral, que contiene insulina. MX2012001461A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0900482A HUP0900482A2 (en) 2009-08-03 2009-08-03 Pharmaceutical formulation for oral administration
PCT/IB2010/053499 WO2011015984A1 (en) 2009-08-03 2010-08-02 Orally administerable pharmaceutical preparation containing insulin

Publications (1)

Publication Number Publication Date
MX2012001461A true MX2012001461A (es) 2012-05-22

Family

ID=89989155

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001461A MX2012001461A (es) 2009-08-03 2010-08-02 Preparacion farmaceutica, de administracion oral, que contiene insulina.

Country Status (15)

Country Link
US (1) US20120129769A1 (enExample)
EP (1) EP2461820A1 (enExample)
JP (1) JP2013501043A (enExample)
KR (1) KR20120088660A (enExample)
CN (1) CN102791282A (enExample)
AU (1) AU2010280418B2 (enExample)
BR (1) BR112012002413A2 (enExample)
CA (1) CA2769620A1 (enExample)
HU (1) HUP0900482A2 (enExample)
IL (1) IL217856A0 (enExample)
MX (1) MX2012001461A (enExample)
RU (1) RU2012109006A (enExample)
UA (1) UA106506C2 (enExample)
WO (1) WO2011015984A1 (enExample)
ZA (1) ZA201201519B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2726091T3 (pl) * 2011-06-29 2020-08-10 Rani Therapeutics, Llc Preparaty lecznicze dostarczane do kanału przewodu jelitowego za pomocą połykalnego urządzenia dostarczającego lek
CA3067713A1 (en) * 2017-06-28 2019-01-03 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Method for determining the risk to develop type 1 diabetes
KR20240171428A (ko) 2023-05-30 2024-12-09 (주)네오비젼 당뇨병 치료를 위한 약물 방출 제어가 가능한 약물 전달용 콘택트렌즈

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172814A (en) 1962-04-06 1965-03-09 Jr Edgar A Ferguson Oral blood sugar lowering compositions
JPS5428807A (en) 1977-08-09 1979-03-03 Hiroyuki Sumi Oral insulin
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
ES2045276T3 (es) 1988-07-21 1994-01-16 Hoffmann La Roche Preparacion de insulina
CA2125284C (en) 1991-12-05 2000-06-20 Jens-Christian Wunderlich Peroral administration form for peptidic medicaments, in particular insulin
JP3047948B2 (ja) * 1992-12-07 2000-06-05 株式会社ツムラ ペプチド類経鼻投与用組成物
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
EP0803255A4 (en) * 1994-06-03 1999-06-30 Tsumura & Co MEDICINAL COMPOSITION
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5970193A (en) 1996-10-24 1999-10-19 Nortel Networks Corporation Data communications structures relating to data shelf configurations
WO1998043615A1 (en) 1997-04-02 1998-10-08 Purdue Research Foundation Method for oral delivery of proteins
WO2000033866A1 (en) 1998-12-04 2000-06-15 Provalis Uk Limited Pharmaceutical compositions containing insulin
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
KR20060015469A (ko) 2003-03-04 2006-02-17 더 테크놀로지 디벨로프먼트 컴퍼니 리미티드 경구용 인슐린 조성물 및 그 제조방법 및 사용방법
JP5103748B2 (ja) * 2005-02-16 2012-12-19 東レ株式会社 医薬組成物
CA2621577C (en) * 2005-09-06 2013-12-24 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
CN101062408B (zh) * 2006-04-27 2010-12-08 深圳市隆阳生物科技有限公司 口服胰岛素复合制剂及其制备方法
JP2008266179A (ja) * 2007-04-19 2008-11-06 Fujifilm Corp 経肺用組成物
EP2514406A1 (en) * 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
RU2494755C2 (ru) * 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков

Also Published As

Publication number Publication date
JP2013501043A (ja) 2013-01-10
ZA201201519B (en) 2013-05-29
US20120129769A1 (en) 2012-05-24
UA106506C2 (uk) 2014-09-10
WO2011015984A1 (en) 2011-02-10
BR112012002413A2 (pt) 2016-03-01
RU2012109006A (ru) 2013-09-10
HUP0900482A2 (en) 2011-03-28
IL217856A0 (en) 2012-03-29
HU0900482D0 (en) 2009-10-28
AU2010280418A1 (en) 2012-03-22
EP2461820A1 (en) 2012-06-13
KR20120088660A (ko) 2012-08-08
CA2769620A1 (en) 2011-02-10
AU2010280418B2 (en) 2015-04-09
CN102791282A (zh) 2012-11-21

Similar Documents

Publication Publication Date Title
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX336412B (es) Nuevos analogos de glucagon.
MY167234A (en) Novel glucagon analogues
UA109949C2 (uk) Композиція і лікарський засіб, які містять ідуронат-2-сульфатазу, і спосіб їх отримання
NZ599774A (en) Melanocortin-1 receptor-specific cyclic peptides
MX2013011175A (es) Analogos de glucagon novedosos.
BR112012017054A2 (pt) "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica"
PH12016500004A1 (en) Pcsk9 vaccine
WO2013186240A3 (en) Exendin-4 peptide analogues
PH12014500923A1 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
UA113729C2 (xx) Мутантний поліпептид інтерлейкіну-2 (il-2)
EA201290549A1 (ru) Пептидный аналог оксинтомодулина
IN2012DN00639A (enExample)
EA201070046A1 (ru) Способ получения лекарственного средства, содержащего тадалафил
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MX2009012922A (es) Vacunacion intradermica de un peptido del virus del papiloma humano.
WO2012049307A3 (en) Novel n-terminally modified insulin derivatives
MX353301B (es) Composiciones tripeptidicas y metodos para tratamiento de diabetes.
PH12013501902A1 (en) Infant formula for use in the prevention of cardiovascular diseases
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
ATE443722T1 (de) Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
AU2010286532A8 (en) Methods of treatment using anti-oxidized LDL antibodies
MX2012001461A (es) Preparacion farmaceutica, de administracion oral, que contiene insulina.
WO2013078376A3 (en) Isoxazole treatments for diabetes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal